Journal
EYE
Volume 23, Issue 1, Pages 181-185Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.eye.6702938
Keywords
eye; bevacizumab; intraocular pressure; intravitreal; pegaptanib; triamcinolone
Categories
Ask authors/readers for more resources
Purpose To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml ( 4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results A total of 212 injections were performed ( 76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise > 10 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP < 35 mmHg, but this difference became less marked with time. Conclusion In our series, most patients receiving intravitreal injections did not require IOP-lowering drops after injection, and none required a paracentesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available